🇺🇸 FDA
Patent

US 10675302

Methods and compositions for targeted cleavage and recombination

granted A61KA61K2035/124A61K35/12

Quick answer

US patent 10675302 (Methods and compositions for targeted cleavage and recombination) held by Sangamo Therapeutics, Inc. expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K2035/124, A61K35/12